Scisparc ltd SPRC.US 總覽分析
美股醫療保健
(SPRC 無簡報檔)
SPRC 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
SPRC 近期報酬表現
38.41%
Scisparc ltd
1.99%
同產業平均
-0.64%
S&P500
與 SPRC 同產業的標的表現
- FEMY Femasys inc價值 3 分趨勢 2 分波段 2 分籌碼 1 分股利 1 分查看更多
SPRC 公司資訊
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.